CG Oncology (NASDAQ:CGON) Stock Keeps “Buy” Rating at Truist Financial

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Truist Financial in a report released on Tuesday, Benzinga reports. They currently have a $100.00 price target on the stock, up from their prior price target of $85.00. Truist Financial‘s price target would indicate a potential upside of 24.38% from the company’s previous close.

Several other research analysts have also recently weighed in on the company. Royal Bank Of Canada cut CG Oncology from an “outperform” rating to a “sector perform” rating and boosted their price target for the stock from $80.00 to $97.00 in a research note on Tuesday. HC Wainwright boosted their target price on CG Oncology from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim lowered their target price on shares of CG Oncology from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Wedbush raised their price target on shares of CG Oncology from $84.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Piper Sandler lifted their price target on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CG Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $94.22.

Check Out Our Latest Report on CGON

CG Oncology Stock Down 5.2%

Shares of CGON opened at $80.40 on Tuesday. CG Oncology has a twelve month low of $37.01 and a twelve month high of $93.95. The company has a market capitalization of $7.18 billion, a P/E ratio of -29.55 and a beta of 0.35. The firm has a 50 day moving average of $68.24 and a 200 day moving average of $66.70.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. On average, sell-side analysts expect that CG Oncology will post -3.00 EPS for the current year.

Insider Activity at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director owned 1,000 shares in the company, valued at approximately $62,060. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CGON. BlackRock Inc. bought a new stake in shares of CG Oncology during the 2nd quarter valued at about $444,509,000. Seven Fleet Capital Management LP lifted its stake in shares of CG Oncology by 24.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after purchasing an additional 371,085 shares during the period. Bank of America Corp DE lifted its stake in shares of CG Oncology by 21.8% in the 1st quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock worth $98,093,000 after purchasing an additional 259,311 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of CG Oncology by 32.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after purchasing an additional 278,751 shares during the period. Finally, EcoR1 Capital LLC boosted its holdings in shares of CG Oncology by 3.5% in the first quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock worth $74,583,000 after buying an additional 37,200 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

Latest CG Oncology News

Investors following CGON have been watching these news items:

  • Positive Sentiment: In the PIVOT-006 Phase 3 trial, cretostimogene cut the risk of bladder-cancer recurrence by 68% versus surveillance (hazard ratio 0.32; p<0.0001). The company reported no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results address an estimated 50,000-patient group with no FDA-approved adjuvant treatment option. PIVOT-006 trial results
  • Positive Sentiment: CG Oncology plans to use the results to support a second Biologics License Application (BLA) for intermediate-risk and high-grade Ta disease in Q2 2027. Separately, following FDA feedback, it expects to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with filing completion anticipated by March 2027.
  • Negative Sentiment: The results are topline and based on preliminary analysis. The FDA could interpret the data differently, request additional studies, delay review, or approve a narrower indication than the company anticipates; cretostimogene remains investigational and is not yet FDA-approved.

About CG Oncology

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-GuĂ©rin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Featured Articles

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.